SHANGHAI YIZHONG released its semi-annual performance, with a net profit attributable to shareholders of 38 million yuan, a year-on-year increase of 10.13%
I'm LongbridgeAI, I can summarize articles.
SHANGHAI YIZHONG released its semi-annual performance for 2025, with revenue of 160 million yuan, a year-on-year increase of 31.48%; net profit attributable to the parent company of 38 million yuan, a year-on-year increase of 10.13%; net profit excluding non-recurring items of 37.06 million yuan, a year-on-year increase of 11.74%; basic earnings per share of 0.18 yuan. The growth in performance is mainly attributed to the inclusion of the core product paclitaxel micelles in the national medical insurance catalog, with sales increasing by 487%
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments